Cure Alzheimer's Fund Cure Alzheimer's Fund

Core Facility for Abeta Microdialysis Drug Discovery Platform

2007, 2008, 2009

In collaboration with an anonymous funder, Cure Alzheimer’s Fund is supporting development of a facility to measure the concentration of Amyloid-beta in real time in the brain of living, behaving mouse models that develop features of AD. The model enables screening for drugs that lower Amyloid-beta directly in the brain in relatively high throughput.

David Holtzman Drug Discovery Drug Screening Projects

Funding to Date

$278,238

Focus

Drug Discovery, Drug Screening Projects

Researchers

David M. Holtzman, M.D.

Related Content:


Fleming APOE Consortium: Investigating Potential Cell Autonomous Neuroprotection of APOE Protective Variants David Holtzman 2024-11-20 2024 Jeffrey L. Morby Prize for Exceptional Research David Holtzman 2024-07-03 Non-Invasive Delivery of IL-2 to the CNS for Local Expansion of Regulatory T Cells and Prevention of Neurodegeneration in Tauopathy Peter M. Tessier David Holtzman 2024-06-26 Exploring Novel Drug Candidates for Alzheimer’s Disease Through Integrative Pathway Analysis and Validation in 3D Cellular Models Doo Yeon Kim Luisa Quinti 2024-02-01 Development of Small Molecule Inhibitors of Cholesterol 25-hydroxylase Anil Cashikar Bahaa Elgendy 2024-02-01 Microbiome Consortium: The Role of Gut Microbial Metabolism in Tau-Mediated Neurodegeneration David Holtzman 2023-11-02 Validation and Characterization of Compounds Modulating Neuroinflammation and Amyloid Beta Uptake in Microglial Cells Ana Griciuc Luisa Quinti 2023-10-25 Identification and Development of CD33 Inhibitors and Pre-RNA Splicing Modulators Subhash Sinha 2023-10-25